November 26th, 2025: Ozempic and Mounjaro Litigation Expands Following New Evidence of Heightened GI Risks A newly released study has increased scrutiny of GLP-1 receptor agonists such as Ozempic, Mounjaro, and Trulicity, linking these medications to substantially higher rates of gastrointestinal complications than older diabetes treatments
For those who do have insurance coverage, it can cost as little as $25/mo
Came promptly and packaged well, easy to order Already 6 lbs down
It runs for 80 weeks (the longest in the program), enrolls a general obesity population without type 2 diabetes, and is designed to be the direct apples-to-apples analogue of SURMOUNT-1 (tirzepatide) and STEP-1 (semaglutide)
Funding This work was supported by grants from Conselho Nacional de Desenvolvimento Cientfico e Tecnolgico (CNPq), Fundao de Amparo Pesquisa do Estado do Rio de Janeiro (FAPERJ) and Universidade Estcio de S (Scholarship for Students: Pibic-UNESA and Pibic-IDOMED)